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Background: Ethnic minority groups have higher prevalence of cardiovascular disease (CVD) and type 2 diabetes
mellitus (T2DM). We assessed general practitioners’ (GPs’) performance with respect to the pharmacological
prevention of CVD in patients with T2DM from different ethnic backgrounds in Oslo.
Methods: Of 1653 T2DM patients cared for by 49 GPs in 2005, 380 had a diagnosis of CVD. Ethnicity was
categorized as Norwegian, South Asian and other. Risk factor levels, medication use, achievement of treatment
targets (HbA1c ≤ 7.5%, systolic blood pressure (SBP) ≤ 140 mmHg, total cholesterol/HDL-cholesterol < 4) and
therapeutic intensity (number of drugs targeting each risk factor) were recorded. Chi-square, Wald tests and
multiple linear regression analyses were used.
Results: Of the 1273 patients receiving primary prevention, 1.5% had their Hb1Ac, 4.8% SBP and 12.7% lipids levels
above treatment thresholds without relevant prescriptions. Among patients on pharmacological therapy, 66%
reached the HbA1c, 62% SBP and 62% lipid target. Proportions not achieving the HbA1c target were 26% in
Norwegians, 38% in South Asians and 29% in others (p = 0.008). Proportions not achieving the SBP target were
42% in Norwegians, 22% in South Asians and 25% in others (p ≤ 0.001). Of those not achieving the HbA1c and SBP
targets, 43% and 35% respectively, used only one agent.
In secondary prevention, 0.8% of the patients had their HbA1c, 0.5% SBP and 7.4% lipid levels above treatment
thresholds without relevant prescriptions. Among patients on pharmacological therapy, 65% reached the HbA1c,
64% SBP and 66% lipid target. Proportions not achieving the HbA1c target were 26% in Norwegians, 47% in South
Asians and 40% in others (p = 0.03). Proportions not achieving the SBP target were 36% in Norwegians, 22% in
South Asians and 56% in others (p = 0.050). Of those not achieving HbA1c and SBP targets, 49% and 21%
respectively, were on mono-therapy.
Conclusions: Norwegian GPs comply reasonably well with guidelines for pharmacological prevention of CVD in
T2DM patients across ethnic groups. However, lipid-lowering therapy was generally underused, and the
achievement of treatment targets for HbA1c in ethnic minorities and for BP in Norwegians could be improved.
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Cardiovascular disease (CVD), in particular coronary
heart disease (CHD) and cerebro-vascular disease, are
the major causes of morbidity and mortality in patients
with diabetes [1,2]. In Europe, ethnic groups with origin
from Asia and Africa have a higher prevalence of type 2
diabetes mellitus (T2DM) [3,4], higher age-adjusted dia-
betes mortality rates [5] and standardised CVD mortality
rates [6] than the majority population.
In several Western countries, improvements in risk
factor levels and better treatment for CHD have con-
tributed to reduced CVD mortality in both the general
population [7-12] and in individuals with diabetes
[13-17]. Data from the UK reveal that these improve-
ments have not to the same extent benefitted ethnic mi-
norities like South Asians [18].
Because patients with highest risk also gain most from
interventions, they should be identified and prioritized
by their general practitioners (GPs) [19]. Pharmacological
therapy to prevent CVD in individual patients should
therefore be based on estimated absolute risk for future
CVD [19,20]. Intensive interventions targeting multiple
risk factors to prevent CVD in T2DM patients with ethnic
minority backgrounds are needed to reduce ethnic dispa-
rities in long term health outcomes [21-23]. To our know-
ledge, only two diabetes specific risk algorithms, those
developed by The United Kingdom Prospective Diabetes
Study (UKPDS) Group [24] and the New Zealand Dia-
betes Cohort Study Group [25], include ethnicity as a risk
factor. However, guidelines must be tailored to fit the
individual. Too intensive glucose-lowering therapy (e.g.
aiming at HbA1c < 6%) may increase mortality in pa-
tients with previous cardiovascular events [26] or in
elderly patients with a long duration of diabetes [27].
Similarly, intensive anti-hypertensive therapy, aiming at
systolic blood pressure (SBP) well below 130 mmHg has
also been questioned due to increased risk for hypotension
and adverse drug reactions [28]. Moreover, interventions
to reduce blood pressure below 120 mmHg have not been
shown to reduce cardiovascular risk [29].
Compared with the majority population, ethnic mi-
nority groups in Norway have a higher prevalence of
self-reported CVD and diabetes [30], increased suscepti-
bility for diabetes for a given level of adiposity [31], and
are on average younger at the time of T2DM diagnosis
[32]. Despite receiving more intensive glucose-lowering
therapy, they also have poorer glycaemic control [32].
Regardless of ethnicity, important processes of care mea-
sures are comparable, but only one in four of T2DM
patients in all ethnic groups, receiving care in general
practice, reach all national treatment targets related to
HbA1c, BP and lipid levels [32].
The aim of this study was to explore GPs’ adherence to
the guidelines for pharmacological primary or secondaryCVD prevention in T2DM patients [33,34], achievements
of treatment targets, the intensity of treatment, poten-
tial overtreatment and to estimate the 10-year risk for
CHD in Norwegian and South Asian patients without
known CVD.
Methods
Design, setting and participants
Cross-sectional data from electronic medical records
(EMRs) from 11 practices (49 GPs’ with 58857 listed pa-
tients) from multiethnic parts of Eastern Oslo were used
[33]. A specially designed data programme was used to
identify patients with diabetes and to capture predefined
data from the EMR from the years 2003–2005. Data
regarding HbA1c, SBP, DBP, microalbuminuria, body
weight and foot examinations were from 2005, for eye
examinations from 2004 or 2005, and for s-cholesterol
and smoking habits from 2003 to 2005. A total of 2064
patients with a diagnosis of diabetes were identified. As
our aim was to explore GPs’ adherence to guidelines for
T2DM, we excluded T1DM patients (n = 103), T2DM
patients with two or more diabetes related hospital visits
the previous 12 months (n = 178) as they also had in-
complete information of current medication, those with
less than six months of follow-up or who had moved or
were deceased (n = 128), or who had incomplete infor-
mation about the country of birth (n = 2), leaving 1653
T2DM patients cared for by their GPs to be included
in the present study. The study was approved by the
Regional Ethics Committee West, the Directorate for
Health and the Data Inspectorate.
Variables
Patients who according to the EMR had a diagnosis of
angina pectoris, previous myocardial infarction, stroke
or transitory ischemic attack, or intermittent claudica-
tion, were categorized as having CVD and thus requiring
secondary prevention (SP) to reduce their risk of new
events. All other patients were considered to require pri-
mary prevention (PP) of CVD.
According to the Norwegian national general practice
diabetes guidelines from 2005 [33,34], diabetes patients
without CVD should have anti-hypertensive therapy if
their BP > 140/90 mmHg, and lipid lowering therapy if
their total cholesterol/HDL-cholesterol ratio > 5.0 and
they had at least one additional risk factor (current anti-
hypertensive therapy, smoking, microalbumiuria or a
family history of premature CVD). For diabetes patients
with CVD, the corresponding treatment thresholds were
BP > 140/90 mmHg and total cholesterol/HDL-cholesterol
ratio ≥ 4.0 irrespective of other risk factors. Treatment
targets were: HbA1c ≤ 7.5%, SBP ≤ 140 mmHg, diastolic
blood pressure (DBP) ≤ 85 mmHg, and total choles-
terol/HDL-cholesterol ratio < 4.0 [33,34].
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factors, patient’s age when diabetes was diagnosed,
disease duration, and prescription data were captured
[32]. For HbA1c, SBP, DBP and lipids, the most recent
results were selected.
Prescription of glucose-lowering therapy (anti-diabetic
agents, insulin or any combinations), anti-hypertensive
(angiotensin converting enzyme inhibitors, calcium chan-
nel blockers, alfa blockers, beta blockers, angiotensin II
receptor antagonists, diuretics, or any combinations),
and lipid-lowering therapy (statins) were dichotomized as
“yes” versus “no” for all three therapy groups. The inten-
sity of treatment was categorized by numbers of agents
used in combination to target elevated BP, and to lower
blood glucose. Because too intensive treatment may
put patients at increased risk for side effects like
hypoglycaemia and hypotension, we identified patients
on glucose-lowering therapy with HbA1c < 6.0%
[27,35] and those on anti-hypertensive therapy with
SBP < 130 mmHg or DBP < 65 mmHg [28].
Ethnicity was based on self-reported country of birth
as recorded in the EMR, and categorized as: Norwegians
(including about 2% from other Scandinavian countries
or Western Europe/North America), South Asians
(Pakistanis, Sri Lankans and Indians), others (from
other low- and middle income countries).
To estimate individual 10-year absolute risk for CHD
for patients without prior CVD in the two largest ethnic
groups (Norwegians and South Asians), we used the
UKPDS Risk Engine version 2 [24], which includes age,
gender, diabetes duration, HbA1c, SBP, total cholesterol,
HDL-cholesterol, smoking status (never, past or current
smoker).
Statistical analyses
Chi- squared, one-way ANOVAs, T-tests and Wald tests
were used to test differences between proportions and
means in the groups. Because HbA1c values were highly
skewed, they were log-transformed and presented as
geometric means (estimates with 95% confidence inter-
vals, transformed back to the original scale). Genera-
lized linear models were applied to estimate means for
the CVD risk factors, the proportions receiving pharma-
cological therapy, and the proportions not reaching
treatment targets, all adjusted for age and gender. The
geometric mean values for HbA1c were also adjusted
for diabetes duration.
HbA1c was recorded in 95%, BP in 91%, total choles-
terol in 94% and smoking habits in 59% of all patients, but
the complete set of variables to be used in the UKPDS risk
engine was available for only 54% of Norwegian and 43%
of South Asian patients. We therefore used multiple im-
putation techniques for individuals with incomplete data
as this is the recommended procedure to limit bias due tomissing data when values are missed at random [36]. Age,
gender, ethnicity, BMI, glucose-lowering therapy, anti-
hypertensive therapy and lipid-lowering therapy were
used as predictors for the imputed values and five im-
puted datasets were created. Multiple regression models
were applied to estimate age- and gender adjusted 10-
year mean risk for cases with complete data and for all
cases after imputation and pooling of the original and
imputed data sets.
Two-sided tests were used and p-values ≤ 0.05 were
considered statistically significant. The analyses were
performed with SPSS 19.0 for Windows and Stata 12.Results
Of the 1653 included patients with T2DM, 1273 (77%)
had no CVD diagnoses (PP group), whereas 380 had one
or more CVD diagnoses (SP group). South Asians were
youngest both in the PP and SP group, being on average
13 and 18 years younger than Norwegians at the time of
diabetes diagnosis (Table 1). In the PP group the pre-
valence of current smoking was lowest among South
Asians (p = 0.001).Primary prevention of CVD
Among the 1273 T2DM patients without established
CVD, 95% had their HbA1c, 90% SBP, 94% total choles-
terol and 58% smoking habits recorded. Differences
between ethnic groups for these processes of care were
minor and significant only for BP-measurements which
were less prevalent among South Asians. In total, 950
(75%) received pharmacological glucose-lowering, 700
(55%) anti-hypertensive and 401 (32%) lipid-lowering the-
rapy. Of those on pharmacological therapy 66% reached
the HbA1c, 62% SBP and 62% lipid target.
Age- and gender-adjusted mean values for SBP, DBP,
HDL-cholesterol and geometric means for HbA1c (also
adjusted for diabetes duration), differed significantly
between ethnic groups (Table 2). In accordance with risk
factor levels, glucose-lowering therapy was prescribed
more often and anti-hypertensives less often to ethnic
minority patients compared with Norwegians, but the
proportion not achieving treatment targets still differed
between ethnic groups. Although lipid-lowering therapy
was prescribed less often to minority patients, the pro-
portion not reaching the lipid target did not differ be-
tween the ethnic groups (Table 2).
Treatment was more intense in those not achieving
targets for hyperglycaemia and SBP (Table 3), but 43.4%
and 35.3% respectively used only one agent. Among the
82 patients on glucose-lowering therapy despite having
HbA1c < 6%, 6 patients were > 75 years, 4 had a diabetes
duration > 10 years and 17 received two or three glucose-
lowering agents (Table 4). Among the 154 patients on
Table 1 Characteristics of 1653 patients with type 2 diabetes receiving pharmacological prevention of CVD by
ethnicity
Characteristicsa Valid cases Norwegians South Asians Othersb Pc
Primary prevention of CVD (n, %) 1273 (100.0) 830 (65.2) 265 (20.8) 178 (14.0)
Males, % 601 47.2 55.7 49.4 0.737
Age, years, mean ( 95% CI) 1273 64.3 (63.4-65.2) 51.0 (49.9-52.1) 54.2 (52.6-55.7) <0.001
Age at diagnosis of diabetes, years, mean (95% CI) 1180 58.0 (57.1-58.9) 44.6 (43.4-45.7) 48.2 (46.4-50.0) <0.001
Diabetes duration, years, mean (95% CI) 1180 6.2 (5.8-6.6) 6.1 (5.4-6.8) 5.1 (4.4-5.8) 0.077
Current smoker, % (95% CI) 742 25.7 (22.6-28.9) 10.8 (8.7-13.2) 21.9 (19.0-25.0) 0.001
Secondary prevention of CVD (n, %) 380 (100.0) 299 (78.7) 57 (15.0) 24 (6.3)
Males, % 227 57.5 68.4 66.7 0.238
Age, years, mean, (95% CI) 380 72.4 (71.2-73.6) 58.2 (55.8-60.6) 65.5 (61.2-69.9) <0.001
Age at diagnosis of diabetes, years, mean, (95% CI) 346 64.7 (63.3-66.0) 46.5 (43.8-49.3) 54.7 (50.1-59.3) <0.001
Diabetes duration, years, mean (95% CI) 346 7.5 (6.7-8.2) 11.5 (9.4-13.5) 9.5 (7.0-11.9) 0.001
Current smoker, % (95% CI) 240 22.4 (17.7-28.2) 12.1 (8.5-16.7) 20.5 (15.8-26.0) 0.405
a CVD: cardiovascular disease (i.e. angina pectoris or myocardial infarction or stroke or intermittent claudication).
b Patients from other regions.
c p-values. Chi-square test was applied to compare proportion between ethnic groups. One-way ANOVAs were applied to compare mean age, age at diagnosis of
diabetes and diabetes duration between ethnic groups.
Table 2 Primary cardiovascular prevention by ethnicity (n=1273): risk factors, pharmacological intervention and
proportion not achieving targets
Characteristicsa Valid cases Norwegians (n=830) South Asians (n=265) Othersb (n=178) Pc
Age- and gender adjusted last available measure of risk factors for CVD (mean, 95% CI)
HbA1c, % 1205 6.9 (6.78-6.94) 7.4 (7.24-7.53) 7.2 (7.01-7.37) <0.001
SBP, mmHg 1142 137.6 (136.4-138.7) 128.6 (126.4-130.8) 131.0 (128.5-133.5) <0.001
DBP, mmHg, 1141 80.3 (79.6-80.9) 76.5 (75.3-77.8) 77.7 (76.2-79.0) <0.001
Total chol, mmol/L 1198 5.3 (5.19-5.33) 5.1 (4.95-5.21) 5.3 (5.14-5.45) 0.049
LDL-chol, mmol/L 793 3.2 (3.09-3.24) 3.2 (3.01-3.31) 3.2 (3.02-3.37) 0.935
HDL-chol, mmol/L 1150 1.4 (1.35-1.40) 1.3 (1.22-1.32) 1.3 (1.29-1.40) 0.001
Total chol/HDL-chol 1150 4.0 (3.96-4.14) 4.2 (4.02-4.34) 4.2 (4.03-4.41) 0.181
Age- and gender adjusted proportion receiving pharmacological therapy (%, 95% CI)
Glucose lowering 1273 71.6 (68.4-74.7) 81.4 (76.6-86.3) 78.7 (72.7-84.8) 0.003
Anti-hypertensive 1273 62.2 (58.7-65.7) 41.2 (34.7-47.7) 42.2 (34.7-49.8) <0.001
Lipid-lowering 1273 35.4 (32.0-38.8) 28.4 (22.7-34.0) 16.2 (10.9-21.6) <0.001
Age- and gender adjusted proportions not achieving treatment targets among patients receiving pharmacological therapy (%, 95% CI)
HbA1c >7.5% 899 25.7 (21.2-30.2) 38.2 (30.5-45.9) 29.2 (21.2-37.3) 0.008
SBP > 140 mmHg 672 41.9 (37.5-46.4) 21.6 (12.2-31.0) 24.5 (14.0-35.1) <0.001
DBP > 85 mmHg 671 25.4 (21.6-29.2) 25.1 (15.9 -34.2) 25.1 (14.7-35.3) 0.996
Total Chol/HDL-chol ≥ 4.0 382 37.3 (31.4-43.1) 33.0 (22.0- 44.1) 48.1 (29.5-66.8) 0.382
a Multiple linear regression was used to estimate means and multiple logistic regression was used to estimate proportions in the groups adjusted for age and
gender. HbA1c was additionally adjusted for diabetes duration. SBP: systolic blood pressure. DBP: diastolic blood pressure. HbA1c was log-transformed before
applying the multiple regression model and the geometric means is presented.
Glucose- lowering therapy: prescription of anti-diabetic agents, insulin or any combinations. Anti-hypertensive therapy: prescription of one or combination of
several agents. Lipid-lowering therapy: prescription of statins.
b Patients from other regions than Western Europe/ North America and SA.
c p-values. Wald tests were applied to test for differences in means and proportions between the groups adjusted for age and gender.
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Table 3 Intensity of pharmacological therapy in T2DM patients receiving cardiovascular prevention by CVD status
Characteristicsa Valid cases Intensity of therapy
One agent Two agents Three or more agents
Primary prevention of CVD
Proportions of patients on glucose lowering therapy achieving and not achieving treatment target (%, 95% CI)
HbA1c ≤ 7.5% 595 63.9 (59.9-67.6) 34.6 (30.9-38.5) 1.5 (0.8-2.9)
HbA1c > 7.5% 304 43.4 (38.0-49.9) 51.0 (45.4-56.6) 5.6 (3.5-8.8)
P < 0.001b
Proportions of patients on anti-hypertensive therapy achieving and not achieving treatment target (%, 95% CI)
SBP ≤ 140 mmHg 414 43.7 (39.0-48.5) 29.0 (24.8-33.5) 27.3 (23.2-31.8)
SBP > 140 mmHg 258 35.3 (29.7-41.3) 28.3 (23.1-34.1) 36.4 (30.7-42.3)
P=0.028b
DBP ≤ 85 mmHg 499 41.1 (36.9-45.5) 28.7 (24.9-32.8) 30.3 (26.4-34.4)
DBP > 85 mmHg 172 39.0 (32.0-46.4) 28.5 (22.2-35.7) 32.6 (26.0-39.9)
P=0.834b
Secondary prevention of CVD
Proportions of patients on glucose lowering therapy achieving and not achieving treatment target (%, 95% CI)
HbA1c ≤ 7.5% 183 58.5 (51.2-65.4) 37.7 (31.4-44.9) 3.8 (1.7-7.8)
HbA1c > 7.5% 97 48.5 (38.8-58.3) 47.4 (37.8-57.3) 4.1 (1.3-10.5)
P=0.269b
Proportions of patients on anti-hypertensive therapy achieving and not achieving treatment target (%, 95% CI)
SBP ≤ 140 mmHg 205 31.7 (25.7-38.4) 30.2 (24.4-36.9) 38.0 (31.7-44.9)
SBP > 140 mmHg 114 21.1 (14.5-29.5) 34.2 (26.1-43.3) 44.7 (35.9-53.9)
P=0.125b
DBP ≤ 85 mmHg 268 28.4 (23.3-34.0) 31.7 (26.4-37.5) 39.9 (34.2-45.9)
DBP > 85 mmHg 51 25.5 (15.4-39.0) 31.4 (20.3-45.1) 43.1 (30.5-56.7)
P=0.888b
a CVD: cardiovascular disease. Treatment target for glucose-lowering therapy: HbA1c ≤ 7.5%, for antihypertensive therapy: systolic blood pressure (SBP) ≤
140 mmHg and diastolic blood pressure (DBP) ≤ 85 mmHg.
b P-values. Chi-square tests were applied to compare proportions of patients receiving one, two or three agents and between those achieving and not achieving
the specific treatment targets.
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receiving two ormore agents.
Among patients without glucose-lowering therapy, 5% had
HbA1c > 7.5% and among those without anti-hypertensive
therapy, 11% had SBP > 140 mmHg. Among patients
without lipid-lowering therapy, 19% had total cholesterol/
HDL-cholesterol ratio > 5. Of the total PP group, 1.5%
had hyperglycaemia, 4.8% hypertension and 12.7%
dyslipidemia without relevant prescriptions. No ethnic dif-
ferences were observed for non-prescription of preventive
pharmacological treatment.
Risk estimation for CHD by the UKPDS engine based
on the 54% of Norwegian and 43% of South Asian patients
with complete datasets, revealed comparable age- and
gender-adjusted 10-year absolute risk (95% confidence
interval) for CHD between the groups (South Asians: 19.0
(17.5-20.5)%, Norwegians: 17.2(16.5-17.9)%). Patients with
(n = 560) and without (n = 535) complete data for CVD
risk estimations were comparable for age at diagnosis,SBP, total cholesterol, and HDL-cholesterol, but differed
for age (60 years vs. 62 years, p = 0.027) diabetes duration
(5.8 years vs. 6.6 years, p = 0.027), HbA1c (7.0% vs. 7.2%,
p = 0.001) and proportions with smoking habits recorded
(100% vs. 20%, p<0.001). After imputation and pooling of
datasets, the age- and gender 10-year risk estimates
for CHD increased for both groups (South Asians: 20.9
(19.7-22.1)%, Norwegians 19.9 (18.7-21.1)%, but ethnic
differences remained insignificant.
Secondary prevention of CVD
In the SP group, the proportions of patients with
recorded CVD risk factors were comparable between
ethnic groups. Pharmacological therapy was more inten-
sive than in the PP group (glucose-lowering drugs: 78%,
anti-hypertensives: 89%, lipid-lowering drugs: 64%).
Among those on pharmacological therapy, 65% reached
the HbA1c, 64% SBP and 66% lipid target, comparable
with the PP group.
Table 4 Potential overtreatment in T2DM patients receiving pharmacological cardiovascular prevention by CVD status
and ethnicity
Characteristicsa Total Norwegians South Asians Other pb
Primary cardiovascular prevention in 1273 patients without known CVD
Proportions of patients on glucose lowering therapy, n/N (%)
HbA1c < 6.0% 82/899 (9.1) 62/563 (11.0) 7/202 (3.5) 13/134 (9.7) 0.006
Proportions of patients on anti-hypertensive therapy, n/N (%)
SBP < 130 mmHg 154/672 (22.9) 98/514 (19.1) 36/90 (40.0) 20/68 (29.4) <0.001
DBP < 65 mmHg 25/671 (3.7) 18/514 (3.5) 6/89 (6.7) 1/68 (1.5) 0.193
Secondary cardiovascular prevention in 380 patients with known CVD
Proportions of patients on glucose lowering therapy, n/N (%)
HbA1c < 6.0% 25/280 (8.9) 24/209 (11.5) 1/52 (1.9) 0/19 (0.0) 0.035
Proportions of patients on anti-hypertensive therapy, n/N (%)
SBP < 130 mmHg 76/319 (23.8) 55/262 (21.0) 17/40 (42.5) 4/17 (23.5) 0.012
DBP < 65 mmHg 26/319 (8.2) 16/262 (6.1) 6/40 (15.0) 4/17 (23.5) 0.009
a CVD: cardiovascular disease. Potential overtreatment with glucose-lowering therapy if HbA1c < 6.0%, with antihypertensive therapy if systolic blood pressure
(SBP) < 130 mmHg or diastolic blood pressure (DBP) < 65 mmHg. n: number of patients on pharmacological therapy with HbA1c < 6.0%, SPB < 130 mmHg or
DBP < 65 mmHg, N: valid cases.
b P-values. Chi-square tests were applied to compare proportions between ethnic groups.
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HDL-cholesterol ratio differed between the ethnic
groups (Table 5). Compared with the PP group, the eth-
nic differences for HbA1c were larger in the SP group.
For patients on pharmacological therapy not achieving
treatment targets, a similar pattern to that found in the
PP group was observed for the ethnic groups (Table 5).
Among the 25 patients on glucose-lowering therapy
with a HbA1c < 6.0%, 12 were > 75 years, 12 had a dia-
betes duration > 10 years and 10 received two or three
glucose-lowering agents (Table 4). Of the 76 patients on
antihypertensive therapy with SBP < 130 mmHg, 21
used two or more anti-hypertensives.
Among patients without glucose-lowering therapy, 4%
had HbA1c > 7.5% while 5% of those without anti-
hypertensive therapy had SBP > 140 mmHg. Among
patients without lipid-lowering therapy, 21% had total
cholesterol/HDL-cholesterol ratio ≥ 4. Of the total SP
group, 0.8% had hyperglycaemia, 0.5% hypertensjon and
7.4% dyslipidemia without relevant prescriptions. No
ethnic differences were observed for these proportions.
Discussion
Our study adds to a sparse literature on primary and
secondary prevention of CVD in T2DM patients of dif-
ferent ethnic origin in general practice. Norwegian GPs
comply reasonably well with the guidelines with respect
to which patients should be prescribed glucose-lowering
and anti-hypertensive therapy across different ethnic
groups of patients, but lipid lowering therapy was rela-
tively underused. However, for those on pharmacological
treatment, both in the PP and SP group, at least one in
three did not reach specified treatment targets, and asignificant proportion of these patients used only one
drug to lower their HbA1c or BP. There seems to be a
potential to safely improve the achievement of treat-
ment targets, especially regarding glucose-lowering
therapy in South Asians and anti-hypertensive therapy
in Norwegians, as very few seemed to be at risk of po-
tentially adverse effects due to overtreatment of hyper-
glycemia or hypertension, especially in the PP group.
Strengths and limitations
Our study population is probably representative for the
population in suburban areas in Eastern Oslo [32].
Other strengths are the detailed recording of prescrip-
tions, HBA1c, BP and lipid values in EMRs together
with physician based diagnosis of diabetes and CVD.
When sampling the data, our focus was on GPs’ adhe-
rence to guidelines, and patients receiving specialist care
were excluded. This represents a limitation in relation
to the total diabetes population. Furthermore, we lack
potentially important information regarding side effects
of pharmacological therapy, lifestyle intervention and
language barriers [37] or health literacy [38] which may
influence adherence with prescribed medication [39].
Missing data limit the validity of our results regarding
the estimated risk for future CHD. Multiple imputation
of missing values may, however, limit this problem if
data are missed at random. Estimates after imputation
therefore probably reflect the whole study population
[36]. The shorter diabetes duration and a better glycaemic
control in patients with complete data for risk estimation
may explain why the risk estimates increased after im-
putation. Estimated CHD risks should nevertheless be
interpreted with caution due to this limitation.
Table 5 Secondary cardiovascular prevention by ethnicity (n=380): risk factors, pharmacological intervention and
proportion not achieving targets
Characteristicsa Valid cases Norwegians (n=299) South Asians (n=57) Othersb (n=24) Pc
Age- and gender adjusted last available measure of risk factors for CVD (mean, 95% CI)
HbA1c, % 360 7.0 (6.84-7.13) 7.9 (7.48-8.28) 7.5 (6.96-8.08) <0.001
SBP, mmHg 356 135.5 (136.3-140.7) 134.3 (128.8-139.8) 138.9 (131–146.7) 0.370
DBP, mmHg 356 78.7 (77.6-79.8) 73.7 (70.9-76.4) 72.5 (68.6-76.4) <0.001
Total chol, mmol/L 349 4.7 (4.58-4.83) 4.6 (4.30-4.87) 4.8 (4.40-5.25) 0.596
LDL-chol, mmol/L 231 2.7 (2.59-2.88) 2.6 (2.30-2.95) 2.8 (2.21-3.34) 0.817
HDL-chol, mmol/L 332 1.3 (1.27-1.36) 1.2 (1.07-1.26) 1.2 (1.10-1.37) 0.013
Total chol/HDL-chol 332 3.7 (3.60-3.88) 4.1 (3.80-4.41) 4.1 (3.67-4.58) 0.049
Age- and gender adjusted proportion receiving pharmacological therapy (%, 95% CI)
Glucose lowering 380 73.8 (68.5-79.0) 96.5 (91.7-101.3) 87.9 (75.0-100.9) <0.001
Anti-hypertensive 380 91.1 (87.8-94.4) 86.6 (77.4-95.9) 80.7 (64.9-96.5) 0.345
Lipid-lowering 380 66.3(60.4-72.1) 60.7(46.1-75.3) 67.5(47.5-87.5) 0.781
Age- and gender adjusted proportions not achieving treatment targets among patients receiving pharmacological therapy (%, 95% CI)
HbA1c >7.5% 280 26.0 (19.4-32.6) 47.2 (31.4- 63.0) 39.6 (16.3-62.9) 0.031
SBP > 140 mmHg 319 35.5 (29.5-41.5) 22.3 ( 7.7 – 36.8) 56.1 (32.2 – 80.0) 0.050
DBP > 85 mmHg 319 16.5 (12.0-21.1) 12.2 (2.3-22.1) 11.6 (−3.6-26.7) 0.645
Total Chol/HDL chol ≥ 4.0 226 31.8 (24.8-39.0) 43.8 (27.6-59.9) 28.5 (7.1 – 50.0) 0.378
a Multiple linear regression was used to estimate means and multiple logistic regression was used to estimate proportions in the groups adjusted for age and
gender. HbA1c was additionally adjusted for diabetes duration. SBP: systolic blood pressure. DBP: diastolic blood pressure. HbA1c was log-transformed before
applying the multiple regression model and the geometric means is presented.
Glucose- lowering therapy: prescription of anti-diabetic agents, insulin or any combinations. Anti-hypertensive therapy: prescription of one or combination of
several agents. Lipid-lowering therapy: prescription of statins.
b Patients from other regions than Western Europe/ North America and SA.
c p-values. Wald tests were applied to test for differences in means and proportions between the groups adjusted for age and gender.
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Norwegian GPs performed good quality diabetes care
with respect to recommended measurements of HbA1c,
SBP and total cholesterol. Our findings here are compar-
able with those reported from a British general practice
study [40]. Although most patients with risk factor levels
above treatment thresholds received pharmacological
therapy according to guidelines, a significant proportion
did not achieve treatment targets despite receiving more
intensive treatment compared with those who reached
targets for HbA1c and SBP. On the other hand, our re-
sults may suggest that patients with higher age, longer
diabetes duration and poorer glycaemic control are more
likely to miss regular appointments. The GPs should pay
particular attention to these patients.
In spite of receiving more intensive glucose-lowering
therapy, the ethnic minority groups still had higher
HbA1c than the Norwegians, both in PP and SP. This
finding is in accordance with previous findings from
British general practice [41,42] and may reflect lower
age at diagnosis [42,43], more pronounced insulin resist-
ance, language barriers or poorer adherence with pre-
scribed therapy [44,45]. In Norwegian T2DM patients,
under-treatment of hypertension or non-adherence with
prescribed medication may represent a challenge.However, a patient’s acceptance of using an intensive
and complex pharmacological regimen for CVD preven-
tion must be considered. The patients’ preferences, cul-
tural factors, skepticism towards polypharmacy [37,39,46]
may all influence GPs’ prescribing practice and patients’
adherence to prescribed therapy and thereby also health
outcomes.
Furthermore, the GPs have to take into account add-
itional costs in terms of adverse drug reactions and
possible interactions in polypharmacy, without added
clinical benefits [28,47]. This is even more relevant as
the latest version of the Norwegian guidelines promote
even lower threshold levels for HbA1c (≤ 7.0%) and BP
(135/80 mmHg), if not otherwise contraindicated [48].
Hypotension may represent barriers for doctors and
patients. However, a recent systematic review and meta-
analysis concluded that intensive anti-hypertensive ther-
apy may provide greater protection against CVD events
and micro-vascular complications, not least in patients
with diabetes [49]. Furthermore, very tight glycaemic
control must be individualized and the possible benefit
of a reduction of microvascular complications must be
weighed against the possibility of hypoglycemia [50] and
increased mortality, especially in elderly patients with
CVD and long diabetes duration [26]. In this study we
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the GPs strategies for shared decision-making with their
patients.
At the time of our study, GPs seemed to focus more
on glucose-lowering and anti-hypertensive than on lipid-
lowering therapy. Since we collected our data, prescrip-
tion of newer glucose-lowering agents and statins in the
general population has increased [51]. Statins have a
modest effect on HDL-cholesterol levels, other strategies
for lipid therapy may be considered, especially for South
Asians where HDL-cholesterol seems to be particularly
important [52].
CHD risk estimation
The age- and gender adjusted 10-year risk for CHD were
lower than corresponding estimates from the US (22.5%)
[53] and in Australian general practice (20.3%) [54]. This
may relate to our exclusion of patients receiving specialist
care, who may be at higher risk for CVD. The UKPDS
Risk Engine is considered to be a useful tool to identify
individuals with T2DM at high risk for CVD in order to
target preventive therapy, but may not provide equally
valid absolute risk estimates in different populations
[55,56]. We do not have cause-specific mortality statistics
for different ethnic minority groups in Norway. However,
lower rates of hypertension and smoking in South Asians
may balance out the effect of higher HBA1c compared
with Norwegians [53].
Conclusions
GPs adhered to guidelines and prescribed pharmacological
therapy for the primary and secondary prevention of CVD
in most T2DM patients with risk factor levels above treat-
ment thresholds in all ethnic groups. However, more
intensive pharmacological therapy may be justified for the
relatively large proportion of patients on pharmacological
therapy that does not reach treatment targets. This relates
in particular to lipid-lowering therapy for all ethnic groups,
antihypertensive therapy for Norwegians and glucose-
lowering therapy in ethnic minorities. Reaching treatment
targets for HbA1c in South Asians is challenging both in
primary and secondary prevention. Future clinical guide-
lines for the primary and secondary prevention of CVD in
patients with T2DM should take into account the role of
ethnicity. Updated risk estimates based on observed CVD
morbidity- and mortality rates for the major ethnic groups
are warranted.
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